Search
Now showing items 1-2 of 2
Comparison of adverse event reporting between adolescent and young adults and older adults with cancer enrolled in Phase II/III clinical trials
(Oklahoma State University Center for Health Sciences, 2023-02-17)
Background: Momentum to improve cancer outcomes in adolescents and young adults (AYAs, diagnosed between 15-39 years of age) has been growing in recent years. However, there remains to be significant barriers to understanding ...
Pediatric autoimmune clinical trial discontinuation and non-publication: An analysis of the National Library of Medicine
(Oklahoma State University Center for Health Sciences, 2023-02-17)
Background: With the rise in pediatric autoimmune diseases in the United States, it is both clinically relevant and timely to analyze the safety, cost-effectiveness, and efficacy of treatment options. The methodical research ...